Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Top Stories

Pfizer/BioNTech Omicron shot shows immune response against BQ.1.1 subvariant

Pfizer/BioNTech Omicron shot shows immune response against BQ.1.1 subvariant 1

(Reuters) -Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.

Antibody levels against the variant rose nearly 9 times in older adults, aged 55 and above, who received the Omicron shot compared to a 2-fold increase in participants with the original shot, according to data posted on the online archive bioRxiv.

BQ.1.1 variant, which is closely related to the BA.5 Omicron subvariant, was estimated to account for about 24.1% of the COVID-19 cases in United States, as of Nov. 12.

Pfizer and BioNtech said the bivalent shot also produced an immune response against newer Omicron subvariants including BA.4.6, BA.2.75.2 and XBB.1.

The companies had recently released data that showed their Omicron-tailored shot produced a strong antibody response in older adults than the original shot after one month against BA.4/5 subvariants.

Based on data from preclinical studies, Omicron-tailored shots made by Pfizer and rival Moderna Inc have already been approved in the United States for adults and for children as young as five years.

(Reporting by Bhanvi Satija in Bengaluru; additional reporting by Manas Mishra; Editing by Krishna Chandra Eluri and Shinjini Ganguli)

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Advertisement

Newsletters with Secrets & Analysis. Subscribe Now